Novo Nordisk Says Famed Diabetes Medicine Ozempic Reduces Risk Of Kidney Disease Progression, Data Shows (UPDATED)
Portfolio Pulse from Vandana Singh
Novo Nordisk A/S announced that its diabetes medicine, Ozempic, significantly reduces the risk of kidney disease progression in type 2 diabetes and chronic kidney disease patients, according to the FLOW study results. The trial, which compared semaglutide 1.0 mg with placebo, achieved its primary endpoint, showing a 24% reduction in kidney disease progression, major adverse cardiovascular events, and death. Novo Nordisk plans to seek regulatory approvals for Ozempic's label expansion in the U.S. and EU in 2024. However, NVO shares dropped 1.79% in premarket trading.
March 05, 2024 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Novo Nordisk's Ozempic demonstrated significant benefits in reducing kidney disease progression in type 2 diabetes and CKD patients, with plans for label expansion in 2024. However, NVO shares fell 1.79% in premarket trading.
The positive trial results for Ozempic in reducing kidney disease progression are significant for Novo Nordisk and could lead to increased demand and broader use upon regulatory approval for label expansion. However, the short-term impact on NVO shares is negative, as indicated by the 1.79% drop in premarket trading. This could be due to market reactions to broader implications of the trial results or other external factors not detailed in the article.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100